Menu Back to Advancing-the-Science-of-Study-Endpoints


DIA’s Conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2018 Conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes.

While we continue to develop this program, check out our Agenda from 2016 to see what's in store! 

This program has been developed in collaboration with the Study Endpoints Community.


Professionals involved in:

  • Industry
  • Academia
  • Government
  • Statistics
  • Clinical Trials
  • Health technology involved in
    • Setting, executing, or evaluating endpoint strategy for drug approval, labeling, promotion, translational science, and market access


  • René  Allard, PhD
    René Allard, PhD Public Disclosure Lead
    Grünenthal GmbH, Germany
  • Emuella  Flood
    Emuella Flood Senior Director, Patient-Reported Outcomes
    ICON, plc., United States
  • J. Jason  Lundy, PhD
    J. Jason Lundy, PhD Principal
    Outcometrix, United States
  • Matthew  Reaney
    Matthew Reaney
    Medical, Sanofi, United Kingdom
  • Ashley F. Slagle, PhD, MS
    Ashley F. Slagle, PhD, MS Principal, Scientific and Regulatory Consulting
    Aspen Consulting, LLC, United States
  • Keith W. Wenzel
    Keith W. Wenzel Senior Director, Solution Incubator
    PAREXEL, United States
  • Michael  Lees
    Michael Lees Head of Value, Evidence and Portfolio Strategy – EUCAN
    Takeda Pharmaceuticals International GmbH, Switzerland
Load More


Registration Questions?

Send Email

Digital Learning Catalog

eLearning Catalog Cover